Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.36 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.36 |
| ▸ | HCN1 | O60741 | 1/20 | 0.31 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
| ▸ | CKS1B | P61024 | 1/20 | 0.30 |
| ▸ | SKP1 | P63208 | 1/20 | 0.30 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29620330 | 0.93 | STK17B (0.38) | STK17BSTK17ANT5ESCN9ACYP3A4 | |
| SCHEMBL4549858 | 0.93 | STK17B (0.38) | STK17BSTK17ANT5ESCN9ACYP3A4 | |
| SCHEMBL30926497 | 0.92 | STK17B (0.37) | STK17BSTK17AHCN1HCN4NT5E | |
| SCHEMBL16076736 | 0.92 | STK17B (0.37) | STK17BSTK17AHCN1HCN4NT5E | |
| SCHEMBL20980308 | 0.88 | STK17B (0.35) | STK17BSTK17ANT5ESCN9ACYP3A4 | |
| SCHEMBL20980306 | 0.88 | STK17B (0.35) | STK17BSTK17ANT5ESCN9ACYP3A4 | |
| SCHEMBL18493681 | 0.84 | STK17B (0.40) | STK17BSTK17ASCN9ACYP3A4SCN10A | |
| SCHEMBL20926953 | 0.83 | STK17B (0.38) | STK17BSTK17ASCN9ACYP3A4SCN10A | |
| SCHEMBL21014691 | 0.83 | PIK3CD (0.32) | SCN9ACYP3A4GSK3BDYRK1ACKS1B | |
| SCHEMBL25957164 | 0.82 | STK17B (0.40) | STK17BSTK17ASCN9ACYP3A4SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | GI Therapeutics, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | G1 THERAPEUTICS, INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190119294-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | G1 THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | STK17B 819/4885STK17A 1110/4885HCN1 4643/4885 |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | STK17B 819/4885STK17A 1110/4885HCN1 4643/4885 |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | MKI67, DPYD, PCNA | STK17B 897/4885STK17A 1014/4885HCN1 4359/4885 |
| US-20190119294-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | TYMS, TYMP, DPYD | STK17B 650/4885STK17A 929/4885HCN1 4717/4885 |
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | TYMS, TYMP, DPYD | STK17B 650/4885STK17A 929/4885HCN1 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.